MedTrace Logo

The Study Will Evaluate the Effect of AZD8683 in Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT01205269 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2014-03-19

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to investigate effects of inhaled AZD8683 compared to placebo in COPD patients.

Conditions

  • Chronic Obstructive Pulmonary Disease (COPD)

Interventions

DRUG

AZD8683, 50 mcg

Dry powder for inhalation, single dose

DRUG

Placebo

Dry powder for inhalation, single dose

DRUG

AZD8683, 200 mcg

Dry powder for inhalation, single dose

Sponsors & Collaborators

Principal Investigators

  • Piotr Kuna, MD Professor · Poland

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-10-31
Primary Completion
2010-12-31
Completion
2010-12-31

Countries

  • Poland

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01205269 on ClinicalTrials.gov